Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Role of tumour markers in monitoring epithelial ovarian cancer.

Literature DB >> 10789720

Role of tumour markers in monitoring epithelial ovarian cancer.

Abstract

Currently the only tumour marker to have a well-defined and validated role in the management of ovarian cancer is CA125. Changes in the level of CA125 can be used as a reliable indication of response or progression according to various criteria, but it does not yet have a clear place in diagnosis or prognosis. Its value as part of a screening tool and during routine follow-up remain the subject of ongoing trials. Other markers remain experimental and do not have a well-defined contribution to make at present.

Entities: Disease Gene

Mesh：

Substances：

Year: 2000 PMID： 10789720 PMCID： PMC2363391 DOI： 10.1054/bjoc.2000.1174

Source DB: PubMed Journal: Br J Cancer ISSN： 0007-0920 Impact factor: 7.640

34 in total

1. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients.

Authors: C F Sier; R Stephens; J Bizik; A Mariani; M Bassan; N Pedersen; L Frigerio; A Ferrari; K Danø; N Brünner; F Blasi
Journal: Cancer Res Date: 1998-05-01 Impact factor: 12.701

2. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125.

Authors: G J Rustin; A E Nelstrop; P McClean; M F Brady; W P McGuire; W J Hoskins; H Mitchell; H E Lambert
Journal: J Clin Oncol Date: 1996-05 Impact factor: 44.544

3. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer.

Authors: I Jacobs; D Oram; J Fairbanks; J Turner; C Frost; J G Grudzinskas
Journal: Br J Obstet Gynaecol Date: 1990-10

4. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography.

Authors: I Jacobs; A P Davies; J Bridges; I Stabile; T Fay; A Lower; J G Grudzinskas; D Oram
Journal: BMJ Date: 1993-04-17

5. Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel.

Authors: J A Bridgewater; A E Nelstrop; G J Rustin; M E Gore; W P McGuire; W J Hoskins
Journal: J Clin Oncol Date: 1999-02 Impact factor: 44.544

6. CA 125 as an independent prognostic factor for survival in patients with epithelial ovarian cancer.

Authors: P Sevelda; M Schemper; J Spona
Journal: Am J Obstet Gynecol Date: 1989-11 Impact factor: 8.661

7. CA 125: a valid marker in ovarian carcinoma patients treated with paclitaxel?

Authors: E M Davelaar; J M Bonfrer; R A Verstraeten; W W ten Bokkel Huinink; P Kenemans
Journal: Cancer Date: 1996-07-01 Impact factor: 6.860

8. Serum CA125 regression in epithelial ovarian cancer: correlation with reassessment findings and survival.

Authors: R E Buller; M L Berman; J D Bloss; A Manetta; P J DiSaia
Journal: Gynecol Oncol Date: 1992-10 Impact factor: 5.482

9. Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses.

Authors: A Gadducci; U Baicchi; R Marrai; M Ferdeghini; R Bianchi; V Facchini
Journal: Gynecol Oncol Date: 1996-02 Impact factor: 5.482

10. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers.

Authors: S J Skates; F J Xu; Y H Yu; K Sjövall; N Einhorn; Y Chang; R C Bast; R C Knapp
Journal: Cancer Date: 1995-11-15 Impact factor: 6.860

56 in total

1. Ascites and a raised serum Ca 125--confusing combination.

Authors: L B Silberstein; A N Rosenthal; S W Coppack; K Noonan; I J Jacobs
Journal: J R Soc Med Date: 2001-11 Impact factor: 5.344

2. The value of abdominal CT scans in decision-making during chemotherapy in ovarian cancer.

Authors: M A L van Lankveld; P H M Peeters; M A van Eijkeren; V C M Koot; P O Witteveen; W P Th M Mali
Journal: Med Oncol Date: 2004 Impact factor: 3.064

3. Lights and shadows of the tumoral marker CA-125 in ovarian cancer.

Authors: A Sánchez Muñoz; A González Martín; C Mendiola Fernández
Journal: Clin Transl Oncol Date: 2008-08 Impact factor: 3.405

4. Specific glycosylation of membrane proteins in epithelial ovarian cancer cell lines: glycan structures reflect gene expression and DNA methylation status.

Authors: Merrina Anugraham; Francis Jacob; Sheri Nixdorf; Arun Vijay Everest-Dass; Viola Heinzelmann-Schwarz; Nicolle H Packer
Journal: Mol Cell Proteomics Date: 2014-05-22 Impact factor: 5.911

5. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer.

Authors: J B Welsh; P P Zarrinkar; L M Sapinoso; S G Kern; C A Behling; B J Monk; D J Lockhart; R A Burger; G M Hampton
Journal: Proc Natl Acad Sci U S A Date: 2001-01-30 Impact factor: 11.205

6. Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response.

Authors: Yu-Li Chen; Ming-Cheng Chang; Chia-Yen Huang; Ying-Cheng Chiang; Han-Wei Lin; Chi-An Chen; Chang-Yao Hsieh; Wen-Fang Cheng
Journal: Mol Oncol Date: 2011-12-20 Impact factor: 6.603

Review 7. Liquid Biopsy in the Clinical Management of High-Grade Serous Epithelial Ovarian Cancer-Current Use and Future Opportunities.

Authors: Lara Paracchini; Maurizio D'Incalci; Sergio Marchini
Journal: Cancers (Basel) Date: 2021-05-14 Impact factor: 6.639